Siponimod

🧮 Dose calculator

Multiple sclerosis (relapsing) · Regimen source: FDA Mayzent · 2.2

• • Genotype CYP2C9 first. *1/*3 or *2/*3: 1 mg from day 5 after a 4-day titration. Swallow whole. Interruption ≥4 days: restart titration. Bradycardia, AV block or prior MI/HF: 6-hour first-dose monitoring. FDA Mayzent · 2.2FDA Mayzent · 2.3FDA Mayzent · 2.5FDA Mayzent · 2.4

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyDangerous / avoid

  Label: can cause fetal harm. Dangerous in pregnancy. FDA Mayzent · 8.1

  “Based on animal data and its mechanism of action, MAYZENT can cause fetal harm when administered to a pregnant woman ( see Data ).”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Mayzent · 8.2

  “Risk Summary There are no data on the presence of siponimod in human milk, the effects of MAYZENT on the breastfed infant, or the effects of the drug on milk production.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Mayzent · 8.4

  “Safety and effectiveness in pediatric patients have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Mayzent · 8.5

  “In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Mayzent · 8.3

  “Contraception Females Before initiation of MAYZENT treatment, women of childbearing potential should be counseled on the potential for a serious risk to the fetus and the need for effective contraception during treatment with MAYZENT [see Use in Specific Populations (8.1)] .”